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Aims Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in
patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular
filtration rate (eGFR) of 15 mL/min/1.73 m2. We evaluated the relationship between the efficacy of vericiguat and
baseline and subsequent changes in renal function.
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Methods
and results
In VICTORIA, core laboratory serum creatinine was measured at baseline (n = 4956) and weeks 16, 32, and 48.
Worsening renal function (WRF), defined as an increase ≥0.3 mg/dL in creatinine from baseline to week 16, was
assessed via a Cox model with respect to subsequent primary events. Mean age was 69 years, 24% were female, and
mean baseline eGFR was 61 mL/min/1.73 m2. During 48 weeks of treatment, the trajectories in eGFR and creatinine
with vericiguat were similar to placebo (P = 0.50 and 0.18). The beneficial effects of vericiguat on the primary outcome
were not influenced by baseline eGFR (interaction P = 0.48). WRF occurred in 15% of patients and was associated
with worse outcomes (adjusted hazard ratio 1.28, 95% confidence interval 1.11–1.47; P< 0.001), but the beneficial
effects of vericiguat on the primary outcome were similar in patients with or without WRF (interaction P = 0.76).
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Conclusion Renal function trajectories were similar between vericiguat- and placebo-treated patients and the beneficial effects
of vericiguat on the primary outcome were consistent across the full range of eGFR and irrespective of WRF.
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Graphical Abstract
The left panel shows no differences in the change in creatinine (P = 0.18) between the vericiguat and placebo groups, as evaluated by the interaction
between treatment and study visit in the model. The right panel shows a natural cubic spline plot showing that the treatment effect of vericiguat on
the primary outcome was similar across the full range of estimated glomerular filtration rate (eGFR) (P = 0.23).
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Introduction
Renal dysfunction, worsening renal function, and hyperkalaemia are
frequently present in patients with heart failure (HF) with reduced
ejection fraction (HFrEF), especially those with severe HF.1,2
Antagonists of the renin–angiotensin–aldosterone system (RAAS)
are the cornerstone of the treatment of patients with HFrEF
and angiotensin-converting enzyme (ACE) inhibitors, angiotensin
receptor blockers (ARBs), angiotensin receptor–neprilysin
inhibitors (ARNI), and mineralocorticoid receptor antagonists
(MRAs) have been shown to reduce (cardiovascular) death and/or
HF hospitalization in patients with HFrEF.3,4 However, the use of
these agents requires monitoring of renal function and electrolytes
and may be hampered by poor renal function and/or high serum
potassium concentrations.1 In a large European registry in patients
with HF, both initiation and up-titration of ACE inhibitors and
ARBs were considerably less frequent in those with a lower
estimated glomerular filtration rate (eGFR), higher N-terminal
pro-brain natriuretic peptide (NT-proBNP), and serum potassium
concentrations.5,6 This presents a major challenge since these
patients have higher risks of cardiovascular death and hospitaliza-
tions for HF and may have even greater need for these treatments.
Accordingly, an unmet need exists for effective therapies in
patients with severe HFrEF and advanced chronic kidney disease
that do not adversely influence renal function and/or potassium
concentrations.
Vericiguat, a soluble guanylate cyclase stimulator, reduced









































. hospitalization in patients with worsening HFrEF from 37.8 to 33.6
events per 100 patient-years [hazard ratio (HR) 0.90, 95% confi-
dence interval (CI) 0.82–0.98].7–9 The VICTORIA trial included
patients with severe HFrEF and a very high primary event rate. An
eGFR of 15 mL/min/1.73 m2 was permitted in VICTORIA and is a
lower threshold than prior randomized clinical HF trials with RAAS
inhibitors.10–14 Therefore, this drug might be of potential benefit
to patients with severe HF irrespective of their baseline renal
function without the need to down-titrate or interrupt therapy if
worsening renal function occurs. It could be argued that vericiguat
might improve renal perfusion based on its potential to improve
endothelial and myocardial function. On the other hand, veri-
ciguat’s modest blood pressure lowering effects might impair renal
perfusion. However, the effects of vericiguat on renal function have
not yet been established in a large cohort of patients with severe
HF and it also remains unknown whether the beneficial effects of
vericiguat are seen both in patients with and without renal dysfunc-
tion. The objective of this study was to evaluate the relationships
between the effects of vericiguat and both baseline and subse-




The design, baseline characteristics, and main results of the VICTO-
RIA trial (NCT02861534) (Vericiguat Global Study in Subjects with
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Heart Failure with Reduced Ejection Fraction) have been published
elsewhere.7–9 In brief, VICTORIA included 5050 patients with HF with
a reduced left ventricular ejection fraction (LVEF <45%) and elevated
natriuretic peptide concentrations who recently experienced an
episode of worsening of HF. Patients were randomly assigned in a 1:1
ratio to receive vericiguat or placebo. The primary outcome of VIC-
TORIA was the composite endpoint of time to cardiovascular death or
first HF hospitalization. Secondary outcomes included time to all-cause
death or first HF hospitalization and time to cardiovascular death. All
patients provided written informed consent and the study protocol




Core laboratory serum creatinine, sodium, and potassium were
measured at baseline and weeks 16, 32, and 48. eGFR was cal-
culated using the Modification of Diet in Renal Disease formula
[eGFR = 175× (SCr)–1.154× (age) –0.203× 0.742 (if female)×1.212
(if black)]. Worsening renal function was defined as an increase
≥0.3 mg/dL in creatinine from baseline to week 16, as this is the most
commonly used definition of worsening renal function in chronic HF.15
Any potential effect on renal function was hypothesized to be evident
by 16 weeks. In addition, week 16 was chosen as a landmark in order
to retain a large sample of patients for the analyses due to the high
early event rate.
Statistical analysis
Continuous variables are described using medians (25th, 75th per-
centiles) and tested for trends across eGFR levels using Spearman
correlations. Categorical variables are presented as frequencies (%)
and tested for trends using trend or Cochran–Mantel–Haenszel
tests, where appropriate. Safety assessments, including syncope,
hyperkalaemia, premature treatment discontinuation, and worsen-
ing renal function by week 16, are described by eGFR group and
treatment arm.
To assess the effect of treatment on changes in electrolytes over
time, a linear mixed model was used so that all available data were uti-
lized in the modelling process. The model was fit with treatment arm,
baseline laboratory values, visit, and the interaction between treat-
ment arm and visit as covariates. The value of the electrolyte at each
follow-up time point was used as the outcome. Repeated measure-
ments within patients were taken into account using an unstructured
correlation matrix. Mean [standard deviation (SD)] of electrolytes at
baseline and follow-up visits were calculated by treatment arm, and the
difference between vericiguat and placebo (95% CI) at each follow-up
visit was derived from the model. In addition to the mean (SD) and
difference, the interaction P-value from each model is presented to
indicate if there was a significant difference in trajectories between
treatment arms over follow-up.
Incidence rates by eGFR level and treatment arm were calculated
as the number of events per 100 patient-years of follow-up. A Cox
proportional hazards model was used to assess if the effect of vericiguat
on the primary and secondary outcomes differed by eGFR level.
The model included treatment arm, eGFR, and their interaction. The
proportional hazards assumption was checked for each variable using



















































































.. The HR with 95% CI comparing vericiguat with placebo within each
eGFR level and the interaction P-value are presented.
As a sensitivity analysis, the interaction between eGFR and random-
ized treatment with respect to the primary outcome was performed
with continuous eGFR. The relationship between eGFR and time to
cardiovascular death or HF hospitalization was non-linear, as assessed
by a natural cubic spline with knots at the 5th, 35th, 65th and 95th
percentiles, and was included as a spline in the interaction model. The
predicted risk of the primary outcome at 1 year was plotted by ran-
domized treatment over all values of eGFR.
Finally, a landmark analysis was performed to determine the rela-
tionship between worsening renal function by week 16 and subsequent
outcomes, and to assess treatment modification by worsening renal
function status on subsequent outcomes. Worsening renal function
was defined as an increase ≥0.3 mg/dL in serum creatinine from
baseline to week 16 and was determined for all patients who had
survived to that point and had week 16 laboratory data available.
The relationship between worsening renal function and outcomes
was evaluated using a Cox proportional hazards model that included
treatment, baseline creatinine, and time from last HF hospitalization
or intravenous diuretics to the week 16 lab date. The interaction
between worsening renal function and treatment was also assessed in
a second model. Finally, additional adjustment variables [age, albumin,
beta-blocker use, bilirubin, chloride, haemoglobin, duration of HF,
NT-proBNP, New York Heart Association (NYHA) class, systolic
blood pressure, race/region, urate, history of anaemia, myocardial
infarction, and peripheral artery disease] were added to these models
to reduce the potential for bias induced by landmarking at week 16.
HRs with 95% CIs and P-values are presented.
All analyses were performed by the Duke Clinical Research Institute
(Durham, NC, USA) using SAS version 9.4 (SAS Institute, Cary, NC,
USA).
Results
From the 5050 patients randomized in VICTORIA, 4956 patients
with baseline renal function measurements available were included
in the present study. Baseline characteristics according to eGFR
≤30 (n = 507), 30–60 (n = 2130), and >60 mL/min/1.73 m2
(n = 2319) are presented in Table 1. Baseline characteristics by
eGFR ≤30 and >30 mL/min/1.73m2 are provided in online sup-
plementary Table S1. Patients in lower eGFR groups were older,
more often female, white and from Western Europe, had slightly
higher LVEF and NYHA class, more comorbidities, more frequent
history of cardiovascular disease, and higher NT-proBNP concen-
trations (all P< 0.001). Patients with an eGFR ≤30 mL/min/1.73 m2
less often received ACE inhibitors, ARBs, and MRAs than those
with an eGFR 30–60 and >60 mL/min/1.73 m2 (P< 0.001); use
of sacubitril/valsartan and beta-blockers was similar between
groups. Safety outcomes by treatment and eGFR category (eGFR
≤30, 30–60, and >60 mL/min/1.73m2) are presented in Table 2.
Safety outcomes by treatment and eGFR category ≤30 and
>30 mL/min/1.73m2 are presented in online supplementary Table
S2. Although hyperkalaemia, treatment discontinuations, and wors-
ening renal function were more prevalent in patients with an eGFR
<30 mL/min/1.73 m2, no differences were apparent between those
on vericiguat vs. those on placebo.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Age, years 69 (60, 76) 75 (67, 80) 72 (65, 79) 64 (55, 71) <0.001
Female sex 1189 (24.0%) 151 (29.8%) 540 (25.4%) 498 (21.5%) <0.001
Race <0.001
Asian 1126 (22.7%) 104 (20.5%) 462 (21.7%) 560 (24.2%)
Black 244 (4.9%) 10 (2.0%) 66 (3.1%) 168 (7.2%)
White 3159 (63.8%) 365 (72.0%) 1448 (68.0%) 1346 (58.1%)
Other 426 (8.6%) 28 (5.5%) 154 (7.2%) 244 (10.5%)
Region <0.001
Asia Pacific 1173 (23.7%) 112 (22.1%) 492 (23.1%) 569 (24.5%)
Eastern Europe 1670 (33.7%) 164 (32.3%) 656 (30.8%) 850 (36.7%)
Latin and South America 717 (14.5%) 41 (8.1%) 274 (12.9%) 402 (17.3%)
North America 537 (10.8%) 52 (10.3%) 248 (11.6%) 237 (10.2%)
Western Europe 859 (17.3%) 138 (27.2%) 460 (21.6%) 261 (11.3%)
Worsening HF event 0.122
HF hospitalization 3–6 months 846 (17.1%) 87 (17.2%) 365 (17.1%) 394 (17.0%)
HF hospitalization within 3 months 3316 (66.9%) 355 (70.0%) 1426 (66.9%) 1535 (66.2%)
IV diuretic for HF (without hospitalization)
within 3 months
794 (16.0%) 65 (12.8%) 339 (15.9%) 390 (16.8%)
BMI, kg/m2 27 (24, 31) 27 (24, 31) 27 (24, 31) 27 (24, 31) 0.455
Ejection fraction, % 30 (23, 35) 30 (25, 36) 30 (24, 35) 28 (21, 35) <0.001
Ejection fraction ≤40% 4580 (92.6%) 469 (93.4%) 1955 (92.0%) 2156 (93.1%) 0.589
NYHA class <0.001
I/II 2930 (59.1%) 259 (51.1%) 1213 (56.9%) 1458 (62.9%)
III/IV 2026 (40.9%) 248 (48.9%) 917 (43.1%) 861 (37.1%)
Medical history
Diabetes 2331 (47.0%) 328 (64.7%) 1068 (50.1%) 935 (40.3%) <0.001
Hypertension 3925 (79.2%) 453 (89.3%) 1776 (83.4%) 1696 (73.1%) <0.001
Hyperlipidaemia 2843 (57.4%) 355 (70.0%) 1315 (61.7%) 1173 (50.6%) <0.001
Anaemia 1053 (21.2%) 207 (40.8%) 548 (25.7%) 298 (12.9%) <0.001
CAD 2815 (56.8%) 362 (71.4%) 1322 (62.1%) 1131 (48.8%) <0.001
History of MI 2090 (42.2%) 273 (53.8%) 972 (45.6%) 845 (36.4%) <0.001
History of stroke 569 (11.5%) 80 (15.8%) 274 (12.9%) 215 (9.3%) <0.001
Prior PCI 1652 (33.3%) 214 (42.2%) 766 (36.0%) 672 (29.0%) <0.001
Tobacco use 2922 (59.0%) 276 (54.4%) 1265 (59.4%) 1381 (59.6%) 0.109
Vitals
SBP, mmHg 119 (109, 131) 120 (109, 135) 119 (109, 131) 118 (108, 130) 0.017
DBP, mmHg 72 (65, 80) 70 (62, 79) 71 (63, 78) 74 (67, 82) <0.001
Pulse, bpm 72 (64, 81) 70 (62, 79) 70 (63, 80) 73 (65, 83) <0.001
SOC medications and devices
ACE or ARB 3641 (73.5%) 289 (57.0%) 1510 (70.9%) 1842 (79.4%) <0.001
Beta-blocker 4614 (93.1%) 473 (93.3%) 1978 (92.9%) 2163 (93.3%) 0.796
Sacubitril/valsartan 717 (14.5%) 61 (12.0%) 348 (16.3%) 308 (13.3%) 0.355
MRA 3487 (70.4%) 227 (44.8%) 1411 (66.2%) 1849 (79.7%) <0.001
Diuretics 4812 (97.1%) 497 (98.0%) 2086 (97.9%) 2229 (96.1%) <0.001
Biventricular pacemaker 724 (14.6%) 88 (17.4%) 391 (18.4%) 245 (10.6%) <0.001
ICD 1370 (27.6%) 156 (30.8%) 697 (32.7%) 517 (22.3%) <0.001
Labs
NT-proBNP 2817 (1554, 5329) 5323 (2790, 10 624) 3316 (1769, 5930) 2253 (1296, 3960) <0.001
BNP 745 (456, 1343) 917 (594, 1700) 754 (476, 1405) 704 (410, 1207) <0.001
Creatinine 1.2 (0.9, 1.6) 2.4 (2.2, 2.8) 1.4 (1.3, 1.7) 0.9 (0.8, 1.0) <0.001
Sodium 140 (138, 142) 140 (138, 142) 140 (138, 142) 140 (138, 142) 0.355
Potassium 4.5 (4.2, 4.8) 4.6 (4.2, 5.0) 4.5 (4.2, 4.9) 4.4 (4.1, 4.7) <0.001
Randomized arm 0.590
Placebo 2482 (50.1%) 246 (48.5%) 1070 (50.2%) 1166 (50.3%)
Vericiguat 2474 (49.9%) 261 (51.5%) 1060 (49.8%) 1153 (49.7%)
Continuous variables are presented as median (25th, 75th percentiles) and categorical variables as frequencies (%). Tests for trend across eGFR strata were performed for all baseline characteristics.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CAD, coronary artery disease; DBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; IV, intravenous; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonists NT-proBNP,
N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SOC, standard of care.
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Table 2 Safety outcomes by treatment and estimated glomerular filtration rate category
eGFR ≤30 mL/min/1.73 m2 30< eGFR ≤60 mL/min/1.73 m2 eGFR >60 mL/min/1.73 m2 Overall
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Syncope 11 (4.2) 10 (4.1) 48 (4.5) 38 (3.6) 41 (3.6) 37 (3.2) 185 (3.7)
Symptomatic hypotension 29 (11.1) 22 (8.9) 109 (10.3) 98 (9.2) 86 (7.5) 72 (6.2) 416 (8.4)
Hyperkalaemia 21 (8.0) 25 (10.2) 71 (6.7) 84 (7.9) 29 (2.5) 39 (3.3) 269 (5.4)
Treatment discontinuation 144 (55.2) 138 (56.1) 436 (41.1) 435 (40.7) 371 (32.2) 368 (31.6) 1892 (38.2)
Reason for discontinuation
Adverse event 30 (20.8) 32 (23.2) 83 (19.0) 75 (17.2) 59 (15.9) 50 (13.6) 329 (17.4)
Death 55 (38.2) 57 ((41.3) 156 (35.8) 173 (39.8) 141 (38.0) 149 (40.5) 731 (38.6)
Lost to follow-up 2 (1.4) 2 (1.4) 2 (0.5) 2 (0.5) 4 (1.1) 7 (1.9) 19 (1.0)
Non-compliance with
study drug
2 (1.4) 6 (4.3) 23 (5.3) 24 (5.5) 22 (5.9) 19 (5.2) 96 (5.1)
Physician decision 30 (20.8) 22 (15.9) 78 (17.9) 70 (16.1) 65 (17.5) 62 (16.8) 327 (17.3)
Protocol deviation 1 (0.7) 1 (0.7) 4 (0.9) 1 (0.2) 3 (0.8) 0 (0.0) 10 (0.5)
Withdrawal by patient 24 (16.7) 18 (13.0) 90 (20.6) 90 (20.7) 77 (20.8) 81 (22.0) 380 (20.1)
Worsening renal function by
16 weeks
47/210 (22.4) 35/184 (19.0) 183/892 (20.5) 173/921 (18.8) 116/1016 (11.4) 92/1041 (8.8) 646/4264 (15.2)
Data presented as n (%).
eGFR, estimated glomerular filtration rate.
Figure 1 Change in serum creatinine (A) and estimated glomerular filtration rate (eGFR, B) over time in vericiguat- and placebo-treated
patients was assessed with a linear mixed model. This figure shows no differences in the change in creatinine (P = 0.18) and eGFR (P = 0.50)
between the vericiguat and placebo groups, as evaluated by the interaction between treatment and study visit in the model.
The trajectories of serum creatinine and eGFR over time
in the vericiguat and placebo groups are presented in Figure 1
and Table 3. During 48 weeks of treatment, the mean decrease
in eGFR was approximately 1 mL/min/1.73 m2 in both groups.
A minor drop in eGFR in the first 16 weeks was observed in
both groups without a between group difference over the first
48 weeks of treatment (P = 0.50). Similarly, the trajectory of serum
creatinine during the first 48 weeks of treatment was similar in
vericiguat- and placebo-treated patients (P = 0.18). Serum sodium
and potassium levels at baseline, and weeks 16, 32, and 48 in the
vericiguat and placebo groups are shown in Table 3 and Figure 2.
There was a significant interaction between visit and treatment for
sodium (Table 2) (P = 0.045); however, this difference was deemed




















.. the two treatment groups at individual time points on serum
potassium concentrations and no significant difference between
the potassium trajectories of the treatment groups (P = 0.68).
The clinical event rate and treatment effect of vericiguat in
patients in the three strata of eGFR are shown in Table 4. Patients
with eGFR ≤30 mL/min/1.73 m2 had much higher rates of car-
diovascular death and HF hospitalizations compared with those
with eGFR 30–60 and >60 mL/min/1.73m2. Online supplemen-
tary Figure S1 shows Kaplan–Meier survival curves of patients with
eGFR 30–60 and >60 mL/min/1.73 m2. Although vericiguat did not
show a statistically significant benefit in the separate subgroups of
eGFR ≤30 and >60 mL/min/1.73 m2, the relative reduction of the
primary endpoint by vericiguat was independent of baseline eGFR
(interaction P-value = 0.17). The clinical event rate and treatment
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Creatinine 0.18
Baseline 1.31 (0.012) 1.30 (0.011) –
Week 16 1.36 (0.014) 1.32 (0.012) 0.026 (0.004 to 0.047) 0.018
Week 32 1.37 (0.015) 1.34 (0.014) 0.021 (−0.006 to 0.049) 0.13
Week 48 1.36 (0.016) 1.37 (0.017) 0.002 (−0.027 to 0.032) 0.88
eGFR 0.50
Baseline 61.82 (0.572) 62.47 (0.569) –
Week 16 60.42 (0.585) 61.99 (0.598) −1.013 (−1.900 to −0.126) 0.025
Week 32 59.84 (0.598) 61.35 (0.617) −0.816 (−1.785 to 0.153) 0.10
Week 48 60.26 (0.686) 60.42 (0.698) −0.400 (−1.494 to 0.695) 0.47
Sodium 0.045
Baseline 139.97 (0.073) 139.92 (0.071) –
Week 16 140.09 (0.071) 140.00 (0.072) 0.055 (−0.117 to 0.226) 0.53
Week 32 140.09 (0.072) 140.20 (0.070) −0.092 (−0.266 to 0.081) 0.30
Week 48 140.19 (0.080) 140.08 (0.077) 0.153 (−0.037 to 0.343) 0.11
Potassium 0.68
Baseline 4.49 (0.011) 4.51 (0.011) –
Week 16 4.44 (0.012) 4.48 (0.011) −0.025 (−0.054 to 0.003) 0.08
Week 32 4.46 (0.012) 4.50 (0.012) −0.031 (−0.061 to −0.001) 0.043
Week 48 4.48 (0.013) 4.50 (0.013) −0.015 (−0.048 to 0.019) 0.39
CI, confidence interval; eGFR, estimated glomerular filtration rate; SE, standard error.
aEstimate obtained from a mixed model fit with treatment, time, their interaction and the baseline lab value.
bSlice P-value is for the comparison of vericiguat to placebo at each time point.
cInteraction P-value for the interaction between treatment and time.
Figure 2 Trajectories of serum sodium (A) and potassium (B) over time in vericiguat- and placebo-treated patients. Differences in trajectory
between vericiguat and placebo groups were evaluated with a linear mixed model. This figure shows a small but significant change in sodium
(P = 0.045) but no difference in change for potassium (P = 0.68) between vericiguat and placebo groups, as assessed via the interaction between
treatment and study visit.
effect of vericiguat in patients in the two strata of eGFR (≤30 and
>30 mL/min/1.73 m2) are shown in online supplementary Table S3.
Again, the relative reduction of the primary endpoint by vericiguat
was independent of baseline eGFR (interaction P-value = 0.14).
Figure 3 shows that the treatment effect of vericiguat on the pri-








. Worsening renal function occurred in 15% of evaluable patients
and was associated with a higher risk of cardiovascular death and
HF hospitalization, both in unadjusted and adjusted analyses (Table
5). However, the beneficial effects of vericiguat on the primary
outcome were similar in patients with or without worsening renal
function (interaction P-value = 0.76).
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3 Natural cubic spline plot depicting the interaction
between estimated glomerular filtration rate (eGFR) and ran-
domized treatment with respect to the primary outcome The
predicted risk of the primary outcome at 1 year was plotted by
randomized treatment over all values of eGFR.
Discussion
In patients with severe HFrEF and a high risk of cardiovas-
cular events, renal function trajectories were similar between
vericiguat- and placebo-treated patients. In addition, vericiguat
reduced the primary composite endpoint of cardiovascular death
or HF hospitalization across the full range of baseline eGFR, from
15 mL/min/1.73 m2 and higher. Worsening renal function was asso-
ciated with worse outcomes, but the beneficial effects of veri-
ciguat were similar in patients with and without worsening renal
function.
One of the unique characteristics of VICTORIA was the
inclusion of patients with eGFR <30 mL/min/1.73 m2. All pivotal
HF trials with RAAS inhibitors only included patients with an
eGFR >30 mL/min/1.73 m2 or with serum creatinine concentra-
tions <221–265 μmol/L.10–14 A recent trial on the effects of
empagliflozin in patients with chronic HF included patients with an
eGFR >20 mL/min/1.73m2.16 Patients in VICTORIA with an eGFR
<30 mL/min/1.73 m2 were sicker, with more comorbidities, higher
NYHA class, higher NT-proBNP, and worse clinical outcomes. The
finding that a lower baseline eGFR is associated with worse out-
comes confirms results shown in many other studies,15 but extends
these findings to eGFR levels between 15–30 mL/min/1.73 m2.
As expected, the use of ACE inhibitors, ARBs, and MRAs was
much lower in patients with an eGFR <30 mL/min/1.73 m2, while
beta-blocker use was similar in patients with impaired and nor-
mal renal function.5,6 These data emphasize that the highest-risk
patients receive the lowest percentage of some of the main life-
saving therapies. Therefore, despite major advances in the treat-
ment of patients with HFrEF, there is still a clinical need for novel
therapies especially for patients with severe HFrEF with an eGFR
<30 mL/min/1.73 m2 and/or hyperkalaemia.
In this study in patients with severe HF and a recent worsen-
ing HF event, mean eGFR showed a decrease of approximately
1 mL/min/1.73 m2 during 48 weeks of treatment. Although the
slope of decline in eGFR was slightly greater during the first
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 5 Association between worsening renal function by week 16 and subsequent clinical outcomes





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HFH or CV deathc 48.4% (249) 30.0% (973) 1.41 (1.22–1.62) <0.001 1.28 (1.11–1.47) <0.001
HFH or all-cause deathd 50.8% (261) 31.7% (1030) 1.40 (1.22–1.60) <0.001 1.24 (1.08–1.43) 0.002
CV deathe 16.3% (107) 10.5% (393) 1.35 (1.08–1.67) 0.007 1.25 (1.01–1.56) 0.044
CI, confidence interval; CV, cardiovascular; HFH, heart failure hospitalization; HR, hazard ratio; WRF, worsening renal function.
aAll models include baseline creatinine and time from prior hospitalization or intravenous diuretics to week 16 visit date (categorized).
bRates computed as the number of events per 100 patient-years of follow-up.
cAdjusted for worsening heart failure event, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, bilirubin, chloride, hemoglobin, duration of heart
failure, gamma-glutamyl transferase, N-terminal pro-brain natriuretic peptide, New York Heart Association class, pulse, QT interval corrected with Fridericia’s formula, urate
and history of: myocardial infarction, peripheral artery disease, percutaneous coronary intervention.
dAdjusted for worsening heart failure event, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, albumin, bilirubin, chloride, hemoglobin, duration of
heart failure, gamma-glutamyl transferase, N-terminal pro-brain natriuretic peptide, New York Heart Association class, pulse, QT interval corrected with Fridericia’s formula,
urate and history of: hyperlipidemia, myocardial infarction, peripheral artery disease.
eAdjusted for age, albumin, beta-blocker use, bilirubin, chloride, hemoglobin, duration of heart failure, N-terminal pro-brain natriuretic peptide, New York Heart Association
class, systolic blood pressure, race/region, urate and history of: anemia, myocardial infarction, peripheral artery disease.
16 weeks in patients taking vericiguat, this minor treatment
difference disappeared after 48 weeks. Also, the development of
worsening renal function was not different between groups.
This analysis further addressed whether the beneficial effects
of vericiguat on the primary endpoint of cardiovascular death
or HF hospitalization were maintained across the full spectrum
of eGFR, ranging from very low to high levels. In the eGFR
<30 mL/min/1.73 m2 subgroup, patients on vericiguat had numer-
ically higher primary event rates compared with placebo, but this
difference was not statistically significant. On the other end of
the spectrum, patients in the eGFR >60 mL/min/1.73 m2 subgroup
also did not show a statistically significant reduction of the primary
endpoint on vericiguat. A statistically significant reduction of the
primary endpoint on vericiguat was observed only in the eGFR
30–60 mL/min/1.73 m2 subgroup. However, there was no signifi-
cant interaction between baseline eGFR and the overall reduction
of the primary endpoint by vericiguat. Similarly, the subpopulation
treatment effect pattern plot (STEPP) analysis showed that the
treatment effect of vericiguat on the primary outcome was similar
across the eight subpopulations. STEPP analysis was specifically
developed to investigate the heterogeneity of treatment effects
on survival outcomes across values of a (continuously measured)
covariate, such as serum creatinine or eGFR.17 From these anal-
yses, we confirm no significant treatment heterogeneity across
the full range of eGFR. Finally, the beneficial effects of vericiguat
on the primary endpoint were similar both in those patients who
developed worsening renal function and those who did not. These
data indicate a similar effect of vericiguat across the full range of
eGFR, where neither those with lower nor higher eGFR have a
greater benefit.
In contrast to the pivotal randomized clinical trials with
inhibitors of the RAAS,10–14 VICTORIA did not exclude patients
with hyperkalaemia. In addition, there was no signal that vericiguat
either increased or decreased serum potassium levels. There-
fore, vericiguat can likely be safely provided to patients with
elevated serum potassium concentrations, including those with























































. This study has both strengths and limitations. The main strength
of this analysis is the large contemporary patient population includ-
ing patients ranging from very low to normal eGFR. In addition,
the collection of samples for analyses across multiple time points
of the study is a particular strength. Although values for the 94
missing eGFR values at randomization were not imputed, there
were no substantial differences between those patients and the
overall cohort. The current study is a post-hoc analysis; however,
an analysis on the effects of vericiguat in patients with an eGFR
below and above 30 mL/min/1.73 m2 was pre-specified.
In conclusion, in patients with severe HF and a recent episode
of worsening HF, renal function trajectories were similar between
patients treated with vericiguat vs. placebo. In addition, the devel-
opment of worsening renal function was not different between
groups. The beneficial effects of vericiguat on the primary outcome
of VICTORIA were consistent across the full range of eGFR irre-
spective of worsening renal function. Therefore, vericiguat might be
of benefit in patients with severe HF irrespective of their baseline
renal function, and this study indicates that there is likely no need
to down-titrate or stop vericiguat when worsening renal function
or hyperkalaemia occurs.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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